Neuroleptika: Neue Substanzen — Neue Indikationen

  • H. Wetzel
  • O. Benkert
Conference paper

Zusammenfassung

Seit den Untersuchungen von Carlsson u. Lindqvist (1963) weiß man, daß klinisch wirksame Neuroleptika Dopaminrezeptoren blockieren, und Mitte der 70er Jahre konnte dies erstmals anhand von Rezeptorbindungsstudien direkt nachgewiesen werden (Burt etal. 1975; Seeman etal. 1975). Obwohl man von der antidopaminergen Wirkung der Neuroleptika nicht zwingend auf einen der Schizophrenie zugrundeliegenden Pathomechanismus Rückschlüsse ziehen kann, stellt doch die antipsychotische Wirksamkeit von Dopaminantagonisten eine der wichtigsten Stützen der mittlerweile weiterentwickelten Dopaminhypothese der Schizophrenie (Crow 1987; McKenna 1987) dar.

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

Literatur

  1. Ahlfors UG, Baastrup PC, Dencker SJ, Elgen K, Lingjaerde O, Pedersen V, Schou M, Aaskoven O (1981) Flupenthixole decanoate in recurrent manic-depressive illness. Acta Psychiatr Scand 64: 226–237PubMedCrossRefGoogle Scholar
  2. Angrist B, Rotrosen J, Gershon S (1980) Responses to apomorphine, amphetamine and neuroleptics in schizophrenic subjects. Psychopharmacology 67: 31–38PubMedCrossRefGoogle Scholar
  3. Arana GW, Goff DC, Friedman H, Ornsteen M, Greenblatt DJ, Black B, Shader RI (1986) Does carbamazepine-induced reduction of plasma haloperidol levels worsen psychotic symptoms? Am J Psychiatry 143: 650–651PubMedGoogle Scholar
  4. Benkert O (1989) Functional classification and response to psychotropic drugs. In: Benkert O, Rickels K, Maier W (eds) Methodology in evaluation of psychotropic. Springer, Berlin Heidelberg New York TokyoGoogle Scholar
  5. Bavas C, Stuppäck C, Unterweger B, Haring C, Fleischhacker WW, Hinterhuber H (1988) Zotepine vs. haloperidol in acute schizophrenia: Results of a double blind trial. Psycho-pharmacology 96 [Suppl]: 205Google Scholar
  6. Benkert O (1989) Functional classification and response to psychotropic drugs. In: Benkert O, Rickels K, Maier W (eds) Methodology in evaluation of psychotropic. Springer, Berlin Heidelberg New York TokyoGoogle Scholar
  7. Benkert O, Hippius H (1986) Psychiatrische Pharmakotherapie, 4. Aufl. Springer, Berlin Heidelberg New York TokyoGoogle Scholar
  8. Benkert O, Holsboer F (1984) Effect of sulpiride in endogenous depression. Acta Psychiatr Scand 69 [Suppl 3111: 43–48CrossRefGoogle Scholar
  9. Bischoff S, Vassout A, Delini-Stula A, Waldmeier P (1986) Interactions of cipazoxapine, citatepine, eresepine, and maroxepine with central dopamine (DA) receptors: Effects of in vivo (3H) spiperone binding, DA metabolism, and behavioral parameters. Pharmacopsychiatry 19: 306–307Google Scholar
  10. Boyer P, Puech AJ, Lecrubier Y (1988) Etude en double insu contre placebo de l’amisulpride (Solian 50) à faible dose chez des schizophrènes purement déficitaires. Ann Psychiatr 3: 321–325Google Scholar
  11. Bunney BS (1984) Antipsychotic drug effects on the electrical activity of dopaminergic neurons. Trends Neurosci 7: 212–215CrossRefGoogle Scholar
  12. Burt DR, Enna SJ, Creese I, Snyder SH (1975) Dopamine receptor binding in the corpus striatum of mammalian brain. Proc Natl Acad Sci USA 72: 4655–4659PubMedCrossRefGoogle Scholar
  13. Carlsson A, Lindqvist M (1963) Effect of chlorpromazine or haloperidol on formation of 3-methoxytyramine and normetanephrine in mouse brain. Acta Pharmacol Toxicol 20: 140–144CrossRefGoogle Scholar
  14. Ceulemans DLS, Gelders YG, Hoppenbrouwers MLJA, Reyntjens AJM, Janssen PAJ ( 1985 a) Effect of serotonin antagonism in schizophrenia: A pilot study with setoperone. Psychopharmacology 85: 329–332Google Scholar
  15. Ceulemans DLS, Hoppenbrouwers MLJA, Gelders YG, Reyntjens AJM (1985b) The influence of ritanserin, a serotonin antagonist, in anxiety disorders: A double-blind placebo-controlled study versus lorazepam. Pharmacopsychiatry 18: 303–305Google Scholar
  16. Closse A, Frick W, Dravid A, Bolliger G, Hauser D, Sauter A, Tobler HJ (1984) Classification of drugs according to receptor binding profiles. Naunyn Schmiedebergs Arch Pharmacol 327: 95–101PubMedCrossRefGoogle Scholar
  17. Cohen JD, Putten T van, Marder S, Berger PA, Stahl SM (1987) The efficacy of piquindone, a new atypical neuroleptic, in the treatment of the positive and negative symptoms of schizophrenia. J Clin Psychopharmacol 7: 324–329PubMedGoogle Scholar
  18. Corsini GU, Del Zompo M, Manconi S, Cianchetti C, Mangoni A, Gessa GL (1977a) Sedative, hypnotic and antipsychotic effects of low doses of apomorphine in man. Adv Biochem Psychopharmacol 16: 645–648PubMedGoogle Scholar
  19. Corsini GU, Del Zompo M, Piccardi MP, Onali PL, Mangoni A (1977b) Evidence for dopamine receptors in the human brain mediating sedation and sleep. Life Sci 20: 1613–1618PubMedCrossRefGoogle Scholar
  20. Corsini GU, Del Zompo M, Piccardi MP, Rachele MG, Gessa GL (1981) Therapeutical and experimental usefulness of apomorphine. Int J Clin Pharmacol Res 1: 127–130Google Scholar
  21. Cowdry RW, Gardner DL (1988) Pharmacotherapy of borderline personality disorder: Alprazolam, carbamazepine, trifluoperazine, and tranylcypromine. Arch Gen Psychiatry 45: 111–119Google Scholar
  22. Crow TJ (1987) The dopamine hypothesis survives, but there must be a way ahead. Br J Psychiatry 151: 460–465PubMedCrossRefGoogle Scholar
  23. Crow TJ, Taylor GR, Tyrrell DAJ (1986) Two syndromes in schizophrenia and the viral hypothesis. In: Ree JM van, Matthysse S (eds) Psychiatric disorders: Neurotransmitters and neuropeptides. Progress in Brain Research, Vol 65. Elsevier, Amsterdam, pp 17–27Google Scholar
  24. Delini-Stula A (1986) Neuroanatomical, neuropharmacological and neurobiochemical target systems for antipsychotic activity of neuroleptics. Pharmacopsychiatry 19: 134–139PubMedCrossRefGoogle Scholar
  25. DeLisi LE, Neckers LM, Weinberger DR, Wyatt RJ (1981) Increased whole blood serotonin concentrations in chronic schizophrenic patients. Arch Gen Psychiatry 38: 647–650PubMedGoogle Scholar
  26. Den Boer JA, Verhoeven WMA, Westenberg HGM (1987) Remoxipride, a novel atypical neuroleptic, in the treatment of schizophrenia. Psychopharmacol Bull 23: 206–210Google Scholar
  27. Dieterle DM, Müller-Spahn F, Ackenheil AM (1988) Comparison of zotepine and perazine in schizophrenia. Psychopharmacology 96 [Supp1]: 340Google Scholar
  28. Donaldson SR, Gelenberg AJ, Baldessarini RJ (1983) The pharmacologic treatment of schizophrenia: A progress report. Schizophr Bull 9: 504–527Google Scholar
  29. Dose M, Apelt S, Bremer DE, Emrich HE (1988) Carbamazepine as adjunct of antipsychotic treatment. Psychopharmacology 96 [Supp1]: 338Google Scholar
  30. Farde L, Wiesel FA, Jansson P, Uppfeldt G, Wahlen A, Sedvall G (1988) An open trial of raclopride in acute schizophrenia. Confirmation of D2-dopamine receptor occupancy by PET. Psychopharmacology 94: 1–7PubMedCrossRefGoogle Scholar
  31. Ferrier IN, Johnstone EC, Crow TJ (1984) Clinical effects of apomorphine in schizophrenia. Br J Psychiatry 144: 341–348PubMedCrossRefGoogle Scholar
  32. Gerbaldo H, Demisch L, Lehmann CO, Bochnik J (1988) The effect of OPC-4392, a partial dopamine receptor agonist, on negative symptoms: Results of an open study. Pharmacopsychiatry 21: 387–388Google Scholar
  33. Goldberg SC, Schulz SC, Schulz PM, Resnick RJ, Hamer RM, Friedel RO (1986) Borderline and schizotypal personality disorders treated with low-dose thiothixene versus placebo. Arch Gen Psychiatry 43: 680–686PubMedGoogle Scholar
  34. Hollister LE, Davis KL, Berger PA (1980) Apomorphine in schizophrenia. Comm Psychopharmacol 4: 277–281Google Scholar
  35. Hoffmann HG (1989) Persönliche Mitteilung — Deutsche Wellcome GmbHGoogle Scholar
  36. Janssen PAJ, Niemegeers CJE, Awouters FHL, Schellekens KHL, Megens AAHP, Meert TP (1988) Risperidone (R 64766), a new antipsychotic with serotonin-S2 and dopamine-D2 antagonistic properties. J Pharmacol Exp Ther 244: 685–693PubMedGoogle Scholar
  37. Kahn RJ, McNair DM, Lipman RS, Covi L, Rickets K, Downing R, Fisher S, Frankenthaler LM (1986) Imipramine and chlordiazepoxide in depressive and anxiety disorders. II. Efficacy in anxious outpatients. Arch Gen Psychiatry 43: 79–85Google Scholar
  38. Kissling W, Cottjans J, Procter AW, Ridley-Siegert A, Kristjansson J, Gudmundson GB, Möller HJ (1988) Antipsychotic efficacy of desenkephalin-γ-endorphin. Multicenter doubleblind comparison with haloperidol. Psychopharmacology 96 [Supp1]: 183Google Scholar
  39. Klein DF (1964) Delineation of two drug-responsive anxiety syndromes. Psychopharmacology 5: 397–408CrossRefGoogle Scholar
  40. Klieser E, Strauss WH (1988) Study to establish the indication for the selective S2 antagonist ritanserin. Pharmacopsychiatry 21: 391–393PubMedCrossRefGoogle Scholar
  41. Leone NF (1982) Response of borderline patients to loxapine and chlorpromazine. J Clin Psychiatry 43: 148–150PubMedGoogle Scholar
  42. Levy MI, Davis BM, Mohs RC, Kendler KS, Mathe AA, Trigos G, Horvath TB, Davis KL (1984) Apomorphine and schizophrenia. Arch Gen Psychiatry 41: 520–524PubMedGoogle Scholar
  43. Liebowitz MR, Klein DF, Quitkin FM, Stewart JW, McGrath PJ (1984) Clinical implications of diagnostic subtypes of depression. In: Post RM, Ballenger JC (eds) Neurobiology of mood disorders. Williams & Wilkins, Baltimore, pp 107–120Google Scholar
  44. Lindström L, Besev G, Stening G, Widerlöv E (1985) An open study of remoxipride, a benzamide derivative, in schizophrenia. Psychopharmacology 86: 241–243PubMedCrossRefGoogle Scholar
  45. Lund Laursen A, Gerlach J (1986) Antipsychotic effect of remoxipride, a new substituted benzamide with selective antidopaminergic activity. Acta Psychiatr Scan 73: 17–21CrossRefGoogle Scholar
  46. McCreadie RG, Morrison D, Eccleston D, Gall RG, Loudon J, Mitchell MJ (1985) An open multicentre study of the treatment of florid schizophrenia with remoxipride. Acta Psychiatr Scand 72: 139–143PubMedCrossRefGoogle Scholar
  47. McCreadie RG, Todd N, Livingston M, Eccleston D, Wyatt JAG, Tait D, Crocket G, Mitchell, Huitfeldt B (1988) A double blind comparative study of remoxipride and thioridazine in the acute phase of schizophrenia. Acta Psychiatr Scand 78: 49–56PubMedCrossRefGoogle Scholar
  48. McKenna PJ (1987) Pathology, phenomenology and the dopamine hypothesis of schizophrenia. Br J Psychiatry 151: 288–301PubMedCrossRefGoogle Scholar
  49. Meltzer HY (1980) Relevance of dopamine autoreceptors for psychiatry: Preclinical and clinical studies. Schizophr Bull 6: 456–475PubMedGoogle Scholar
  50. Mita T, Hanada S, Nishino N, Kuno T, Nakai H, Yamadori T, Mizoi Y, Tanaka C (1986) Decreased serotonin S2 and increased dopamine D2 receptors in chronic schizophrenics. Biol Psychiatry 21: 1407–1414PubMedCrossRefGoogle Scholar
  51. Möller HJ, Kissling W, Dietzfelbinger T, Stoll KD, Wendt G (1989) Efficacy and tolerability of a new antipsychotic compound ( Savoxepine ): Results of a pilot study. Pharmacopsychiatry 22: 38–41Google Scholar
  52. Moore NC, Meyendorff E, Yeragani V, LeWitt PA, Gershon S (1987) Tiaspirone in schizophrenia. J Clin Psychopharmacol 7: 98–101PubMedCrossRefGoogle Scholar
  53. Montgomery SA, Montgomery D (1982) Pharmacological prevention of suicidal behavior. J Affective Disord 4: 291–298CrossRefGoogle Scholar
  54. Nair NPV, Lal S, Bloom DM (1986) Cholecystokinin and schizophrenia. In: Ree JM van, Matthysse S (eds) Psychiatric disorders: Neurotransmitters and neuropeptides. Progress in Brain Research, Vol 65. Elsevier, Amsterdam, pp 237–258Google Scholar
  55. Olbrich R, Schanz H (1988) The effect of the partial dopamine agonist terguride on negative symptoms in schizophrenics. Pharmacopsychiatry 21: 389–390PubMedCrossRefGoogle Scholar
  56. Peroutka SJ, Snyder SH (1980) Relationship of neuroleptic drug effects at brain dopamine, serotonin, a-adrenergic and histamine receptors to clinical potency. Am J Psychiatry 137: 1518–1522PubMedGoogle Scholar
  57. Pichot P, Boyer P (1988) Etude multicentrique contrôlée en double insu: Amisulpride (Solian 200) versus halopéridol à forte dose dans les états psychotiques aigus. Ann Psychiatr 3: 326–332Google Scholar
  58. Pöldinger W, Sieberns S (1983) Depression-inducing and antidepressive effects of neuroleptics. Neuropsychobiology 10: 131–136PubMedCrossRefGoogle Scholar
  59. Ree JM van, Verhoeven WMA, Claas FHJ, De Wied D (1986) Antipsychotic action of y-type endorphins: Animal and human studies. In: Ree JM van, Matthysse S (eds) Psychiatric disorders: Neurotransmitters and neuropeptides. Progress in Brain Research, Vol 65. Elsevier, Amsterdam, pp 221–235Google Scholar
  60. Robertson MM, Trimble MR (1982) Major tranquillisers used as antidepressants. J Affective Disord 4: 173–193CrossRefGoogle Scholar
  61. Rüther F, Hippius H (1982) Neuroleptika in niedriger Dosierung als Tranquilizer? MMW 124: 683–684Google Scholar
  62. Seeman P, Chau-Wong M, Tedesco J, Wong K (1975) Brain receptors for antipsychotic drugs and dopamine: Direct binding assays. Proc Natl Acad Sci USA 72: 4376–4380Google Scholar
  63. Serban G, Siegel S (1984) Response of borderline and schizotypal patients to small doses of thiothixene and haloperidol. Am J Psychiatry 141: 1455–1458PubMedGoogle Scholar
  64. Smith RC, Tamminga CA, Davis JA (1977) Effect of apomorphine on schizophrenic symptoms. J Neural Transm 40: 171–176PubMedCrossRefGoogle Scholar
  65. Soloff PH, George A, Nathan RS, Schulz PM, Ulrich RF, Perel JM (1986) Progress in pharmacotherapy of borderline disorders: A double-blind study of haloperidol, amitriptyline, and placebo. Arch Gen Psychiatry 43: 691–697Google Scholar
  66. Spiker DG, Cofsky Weiss J, Dealy RS, Griffin SJ, Hanin I, Neil 3F, Perel JM, Rossi AJ, Soloff PH (1985) The pharmacological treatment of delusional depression. Am J Psychiatry 142: 430–436Google Scholar
  67. Tamminga CA, Gotts MD, Miller MR (1983) N-propyl-norapomorphine in the treatment of schizophrenia. Acta Pharm Suec 2 [Suppl]: 153–158Google Scholar
  68. Tamminga CA, Schaffer MH, Smith RC (1978) Schizophrenic symptoms improve with apomorphine. Science 200: 567–568PubMedCrossRefGoogle Scholar
  69. Verhoeven WMA, Ree JM van, Heezius-van Bentum A, de Wied D, Praag HM van (1982) Antipsychotic properties of des-enkephalin-y-endorphin in treatment of schizophrenic patients. Arch Gen Psychiatry 39: 648–654Google Scholar
  70. Weissbach A, Bardeleben U von, Benkert O, Holsboer F (1988) Clinical efficacy and neuroendocrine effects of zotepine. Psychopharmacology 96 [Suppl]: 337Google Scholar
  71. Wetzel H, Benkert O (1987) Beta-Blocker bei psychiatrischen Erkrankungen. In: Grosdanoff P et al. (Hrsg) Beta-Rezeptoren and Beta-Rezeptorblocker. De Gruyter, Berlin, S 339–349Google Scholar
  72. Wetzel H, Heuser I, Benkert 0 (1988) Benzodiazepines for catatonic symptoms, stupor and mutism. Pharmacopsychiatry 21: 394–395Google Scholar
  73. Wiedemann K, Benkert O, Holsboer F (1989) B-HT 920 — a novel dopamine autoreceptor agonist in the treatment of patients with schizophrenia. Pharmacopsychiatry (Submitted)Google Scholar
  74. White FJ, Wang RY (1986) Effects of tiaspirone (BMY-13859) and a chemical congener (BMY-13980) on A9 and A10 dopamine neurons in the rat. Neuropharmacology 25: 995–1001PubMedCrossRefGoogle Scholar
  75. Woggon B, Angst J, Bartels M, Heinrich K, Hippius H, Koukkou M, Krebs E, Küfferle B, Müller-Oberlinghausen B, Pöldinger W, Rüther E, Schied HW (1984) Antipsychotic efficacy of fluperlapine. An open multicenter trial. Neuropsychobiology 11: 116–120Google Scholar
  76. Yamawaki S (1987) Profiles of clinical efficacy and pharmacological action of zotepine. Pharmacopsychiatry 20 [Special Issue I]: 4–7PubMedCrossRefGoogle Scholar
  77. Yasuda Y, Kikuchi S, Suzuki S, Tsutsui M, Yamada K, Hiyama T (1988) 7-[3-(4-[2,3dimethylphenyl1piperazinyl)propoxy]-2(1H)-quinolone (OPC-4392), a presynaptic dopamine autoreceptor agonist and postsynaptic D2 receptor antagonist. Life Sci 42: 1941–1954Google Scholar

Copyright information

© Springer-Verlag Berlin Heidelberg 1990

Authors and Affiliations

  • H. Wetzel
  • O. Benkert
    • 1
  1. 1.Psychiatrische KlinikUniversität MainzMainzDeutschland

Personalised recommendations